Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer

BMC Genomics

Volumn 16, Issue 1, 2015, Pages

  Krishnan, Preethi ^a   Ghosh, Sunita ^a,b   Wang, Bo ^c   Li, Dongping ^c   Narasimhan, Ashok ^a   Berendt, Richard ^a,b   Graham, Kathryn ^a   Mackey, John R ^a,b   Kovalchuk, Olga ^c   Damaraju, Sambasivarao ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

Breast cancer; microRNA; miR 574 3p; miR 660 5p; Next generation sequencing; Overall survival; Prognostic marker; Recurrence free survival; Reduction mammoplasty; TCGA

Indexed keywords

MICRORNA; MICRORNA 146B 5P; MICRORNA 15A 5P; MICRORNA 196A 5P; MICRORNA 210 3P; MICRORNA 221 3P; MICRORNA 27A 3P; MICRORNA 374A 3P; MICRORNA 374A 5P; MICRORNA 425 5P; MICRORNA 574 3P; MICRORNA 660 5P; MICRORNA 769 5P; MICRORNA 99B 5P; UNCLASSIFIED DRUG; MIRN574 MICRORNA, HUMAN; MIRN660 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE ONTOLOGY; GENE TARGETING; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 84942521189     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-1899-0     Document Type: Article

References (88)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr .
2. Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity. J Biol. 2008;7(2):6.
3. Ribelles N, Perez-Villa L, Jerez J, Pajares B, Vicioso L, Jimenez B, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res. 2013;15(5):R98.
4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.
5. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009.
6. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005;102(10):3738-43.
7. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2007;26(10):1507-16.
8. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262-72.
9. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer. 2007;7(7):545-53.
10. Bertoli G, Cava C, Castiglioni I. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics 2015 06/17;5(10):1122-1143.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
12. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54.
13. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855-62.
14. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318(5858):1931-4.
15. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495-500.
16. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10(1):42-6.
17. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997-1006.
18. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48-57.
19. Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 2010;59(5):579-85.
20. Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014;5(5):1174-84.
21. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132(7):1602-12.
22. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013;19(16):4477-87.
23. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Borresen-Dale A, et al. A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple Negative Breast Cancer Patients. Clinical Cancer Research 2014;21(5):1207-1214.
24. Tam S, de Borja R, Tsao MS, McPherson JD. Robust global microRNA expression profiling using next-generation sequencing technologies. Lab Investig. 2014;94(3):350-8.
25. Liu J, Jennings SF, Tong W, Hong H. Next generation sequencing for profiling expression of miRNAs: technical progress and applications in drug development. J Biomed Sci Eng. 2011;4(10):666-76.
26. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011;71(13):4443-53.
27. Volinia S, Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A. 2013;110(18):7413-7.
28. Liu N, Cui RX, Sun Y, Guo R, Mao YP, Tang LL, et al. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer. 2014;134(6):1359-68.
29. Hannafon BN, Sebastiani P, de las Morenas A, Lu J, Rosenberg CL. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res. 2011;13(2):R24.
30. Wagner E, Liu Y, Schneider B, Storniolo AM, Han J, He C. Abstract 3268: Differences in expression of lncRNAs in breast tumor, adjacent normal-appearing breast tissue, and normal breast tissue from healthy donors. Cancer Res. 2014;74(19):3268-8.
31. Bastani M, Vos L, Asgarian N, Deschenes J, Graham K, Mackey J, et al. A Machine Learned Classifier That Uses Gene Expression Data to Accurately Predict Estrogen Receptor Status. PLoS ONE. 2013;8(12):e82144.
32. Shalaby T, Fiaschetti G, Baumgartner M, Grotzer MA. MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons. Int J Mol Sci. 2014;15(11):21554-86.
33. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42(D1):D68-73.
34. Sana J, Radova L, Lakomy R, Kren L, Fadrus P, Smrcka M, et al. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. Carcinogenesis. 2014;35(12):2756-62.
35. Xiong J, Bing Z, Su Y, Deng D, Peng X. An integrated mRNA and microRNA expression signature for glioblastoma multiforme prognosis. PLoS ONE. 2014;9(5):e98419.
36. Wang L, Zhu M, Ren A, Wu H, Han W, Tan R, et al. A Ten-MicroRNA Signature Identified from a Genome-Wide MicroRNA Expression Profiling in Human Epithelial Ovarian Cancer. PLoS ONE. 2014;9(5):e96472.
37. Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, Malapelle U, et al. Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. BioMed Res Int. 2014;2014:840921.
38. Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 2012;13(4):468-75.
39. Zhu D, Zhu W, Fang C, Fan L, Zou Z, Wang Y, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012;33(7):1294-301.
40. Wu X, Pu X, Zhao Z, Zhao Y, Kang X, Wu W, et al. The expression profiles of microRNAs in Kaposi’s sarcoma. Tumor Biol. 2014;36(1):437-446.
41. Liu X, He M, Hou Y, Liang B, Zhao L, Ma S, et al. Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol Rep. 2013;29(4):1415-20.
42. Xiao G, Tang H, Wei W, Li J, Ji L, Ge J. Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer. Gastroenterol Res Pract. 2014;2014:8.
43. Tafsiri E, Darbouy M, Shadmehr M, Zagryazhskaya A, Alizadeh J, Karimipoor M. Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features. Tumor Biol. 2014;36(3):1603-1612.
44. Renjie W, Haiqian L. MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer Lett. 2015;356(2):568-78.
45. Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Molecular Oncology. 2014;8(5):874-83.
46. Shinden Y, Akiyoshi S, Ueo H, Nambara S, Saito T, Komatsu H, et al. Diminished Expression of MiR-15a Is an Independent Prognostic Marker for Breast Cancer Cases. Anticancer Res. 2015;35(1):123-7.
47. Wang W, Liu L, Li G, Chen Y, Li C, Jin D, et al. Combined Serum CA19-9 and miR-27a-3p in Peripheral Blood Mononuclear Cells to Diagnose Pancreatic Cancer. Cancer Prev Res. 2013;6(4):331-8.
48. Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K, et al. miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1. Int J Oncol. 2013;42(2):757-66.
49. Tang W, Zhu J, Su S, Wu W, Liu Q, Su F, et al. MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival. PLoS ONE. 2012;7(12):e51702.
50. Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer. 2015;136(4):854-62.
51. Peng WZ, Ma R, Wang F, Yu J, Liu ZB. Role of miR-191/425 cluster in tumorigenesis and diagnosis of gastric cancer. Int J Mol Sci. 2014;15(3):4031-48.
52. Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther. 2013;14(12):1104-12.
53. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, et al. MicroRNA Classifiers for Predicting Prognosis of Squamous Cell Lung Cancer. Cancer Res. 2009;69(14):5776-83.
54. Lee YS, Lim YS, Lee J, Wang S, Park H, Kim SY, et al. Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. Oral Oncol. 2015;51(1):77-83.
55. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. Journal of Cancer. 2013;4(5):350-7.
56. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3(5):279-90.
57. Kim BH, Hong SW, Kim A, Choi SH, Yoon SO. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 2013;107(5):505-10.
58. Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol. 2014;35(5):4057-66.
59. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun. 2011;406(1):70-3.
60. Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, et al. MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer. 2013;109(10):2714-23.
61. Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, et al. MicroRNA-374a activates Wnt/Î2-catenin signaling to promote breast cancer metastasis. J Clin Invest. 2012;123(2):566-79.
62. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE. 2011;6(6):e20980.
63. Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: A meta-analysis. Gene. 2012;507(2):135-8.
64. Yang G, Han D, Chen X, Zhang D, Wang L, Shi C, et al. MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IkBaα both in vitro and in vivo. Neuro-Oncology. 2014;16(5):652-61.
65. Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, et al. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 2014;5(24):12908-15.
66. Suh Y, Raulf N, Gñken J, Lawler K, Urbano TG, Bullenkamp J, et al. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance. Int J Cancer 2015 01/01:n/a-n/a.
67. Xu X, Wang W, Su N, Zhu X, Yao J, Gao W, et al. miR-374a promotes cell proliferation, migration and invasion by targeting SRCIN1 in gastric cancer. FEBS Lett. 2015;589(3):407-13.
68. Mu YP, Tang S, Sun WJ, Gao WM, Wang M, Su XL. Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features and prognosis in gastric cancer. Asian Pac J Cancer Prev. 2014;15(20):8893-900.
69. Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 2009;18(1):50-5.
70. Li J, Kong F, Wu K, Song K, He J, Sun W. miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer. Mol Med Rep. 2014;10(5):2613-20.
71. Hummel R, Sie C, Watson DI, Wang T, Ansar A, Michael MZ, et al. MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol. 2014;20(40):14904-12.
72. Li X, Yan P, Shao Z. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene. 2009;28(44):3937-48.
73. Yu L, Tumati V, Tseng S, Hsu F, Kim DN, Hong D, et al. DAB2IP Regulates Autophagy in Prostate Cancer in Response to Combined Treatment of Radiation and a DNA-PKcs Inhibitor. Neoplasia. 2012;14(12):1203-12.
74. Shen Y, Kong Z, Wan F, Wang H, Bian X, Gan H, et al. Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer Sci. 2014;105(6):704-12.
75. de Haro M, Al-Ramahi I, Jones KR, Holth JK, Timchenko LT, Botas J. Smaug/SAMD4A Restores Translational Activity of CUGBP1 and Suppresses CUG-Induced Myopathy. PLoS Genet. 2013;9(4):e1003445.
76. Pavon-Eternod M, Gomes S, Rosner MR, Pan T. Overexpression of initiator methionine tRNA leads to global reprogramming of tRNA expression and increased proliferation in human epithelial cells. RNA. 2013;19(4):461-6.
77. Chen L, Han L, Wei J, Zhang K, Shi Z, Duan R, et al. SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. Sci Rep. 2015;5:8588.
78. Yan H, Wu Q, Sun C, Ai L, Deng J, Zhang L, et al. piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma. Leukemia. 2015;29(1):196-206.
79. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-91.
80. Bernstein L, Lacey JV. Receptors, Associations, and Risk Factor Differences by Breast Cancer Subtypes: Positive or Negative? J Natl Cancer Inst. 2011;103(6):451-3.
81. Sapkota Y, Ghosh S, Lai R, Coe BP, Cass CE, Yasui Y, et al. Germline DNA Copy Number Aberrations Identified as Potential Prognostic Factors for Breast Cancer Recurrence. PLoS ONE. 2013;8(1):e53850.
82. Dobbin KK, Simon RM. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics. 2007;8(1):101-17.
83. Dobbin KK, Zhao Y, Simon RM. How Large a Training Set is Needed to Develop a Classifier for Microarray Data? Clin Cancer Res. 2008;14(1):108-14.
84. Kolbert CP, Feddersen RM, Rakhshan F, Grill DE, Simon G, Middha S, et al. Multi-Platform Analysis of MicroRNA Expression Measurements in RNA from Fresh Frozen and FFPE Tissues. PLoS ONE. 2013;8(1):e52517.
85. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
86. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5(7):621-8.
87. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
88. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.